Loading clinical trials...
Loading clinical trials...
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Conditions
Interventions
Posaconazole
ABT-199
+2 more
Locations
23
United States
City of Hope /ID# 129718
Duarte, California, United States
University of California, Davis Comprehensive Cancer Center /ID# 129719
Sacramento, California, United States
Univ of Colorado Cancer Center /ID# 127859
Aurora, Colorado, United States
Emory Midtown Infectious Disease Clinic /ID# 129715
Atlanta, Georgia, United States
Northwestern University Feinberg School of Medicine /ID# 128741
Chicago, Illinois, United States
The University of Chicago Medical Center /ID# 128742
Chicago, Illinois, United States
Start Date
October 6, 2014
Primary Completion Date
June 16, 2022
Completion Date
June 16, 2022
Last Updated
May 16, 2023
NCT06656494
NCT06859424
NCT05007873
NCT07347171
NCT07254312
NCT02143830
Lead Sponsor
AbbVie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions